Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Long-Term Debt Repayments (2017 - 2021)

Protalix BioTherapeutics has reported Long-Term Debt Repayments over the past 4 years, most recently at $4.1 million for Q1 2021.

  • Quarterly results put Long-Term Debt Repayments at $4.1 million for Q1 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $4.1 million (changed N/A YoY), and the annual figure for FY2024 was $20.4 million, changed.
  • Long-Term Debt Repayments for Q1 2021 was $4.1 million at Protalix BioTherapeutics, up from $430000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for PLX hit a ceiling of $6.7 million in Q1 2017 and a floor of $11668.0 in Q1 2018.
  • Median Long-Term Debt Repayments over the past 4 years was $2.5 million (2018), compared with a mean of $2.8 million.
  • Peak annual rise in Long-Term Debt Repayments hit 99.83% in 2018, while the deepest fall reached 99.83% in 2018.
  • Protalix BioTherapeutics' Long-Term Debt Repayments stood at $6.7 million in 2017, then crashed by 62.38% to $2.5 million in 2018, then plummeted by 83.0% to $430000.0 in 2020, then surged by 850.23% to $4.1 million in 2021.
  • The last three reported values for Long-Term Debt Repayments were $4.1 million (Q1 2021), $430000.0 (Q3 2020), and $2.5 million (Q2 2018) per Business Quant data.